| Description | TP-3654 is a second-generation Pim kinase inhibitor (Ki values against Pim-1/3: 5/42 nM). |
| In vitro | TP-3654 shows potent PIM-1 specific cellular activity in the PIM-1/BAD overexpression system with an average EC50 of 67 nM. TP-3654 treatment reduces levels of phospho-BAD in vitro using the bladder cancer cell line UM-UC-3. TP-3654 reduces colony growth of T24 and UM-UC3 cells, confirming the PIM-1–dependent growth for both cell lines [1]. |
| In vivo | TP-3654（200 mg/kg，i.g.）显著降低了通过体积（游标卡尺）和最终肿瘤重量测量的UM-UC-3和PC-3肿瘤生长，同时未观察到体重显著变化或明显不良毒性[1]。 |
| Cell experiments | 1 μM TP-3654 is tested against 336 kinases at a concentration of 10 μM ATP. IC50 determinations of phosphoinositide 3-kinase (PI3K) (α, β, δ, and γ) and all kinases inhibited by >50% from the initial screen are performed using 10-dose, three-fold serial dilutions of TP-3654 starting with 10 μM at Km ATP concentrations for each kinase[1]. |
| Animal experiments | When tumours of mice reach 100 to 200 mm3 by calliper measurement, mice are randomized and oral dosing of TP-3654 or vehicle control began and continued every day for 5 days with 2 days off for 18 to 21 days. Tumour volumes and body weights were determined twice a week[1]. |
| Target activity | Pim1:5 nM (Ki), Pim3:42 nM (Ki), Pim2:239 nM (Ki) |
| molecular weight | 418.46 |
| Molecular formula | C22H25F3N4O |
| CAS | 1361951-15-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (131.43 mM) |
| References | 1. Foulks JM, et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia. 2014 May;16(5):403-12. |